Chicago Equity Partners LLC grew its position in Exelixis, Inc. (NASDAQ:EXEL) by 9.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 196,850 shares of the biotechnology company’s stock after buying an additional 16,555 shares during the quarter. Chicago Equity Partners LLC’s holdings in Exelixis were worth $5,984,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of Exelixis in the 3rd quarter worth $120,000. Fisher Asset Management LLC purchased a new stake in shares of Exelixis in the 3rd quarter worth $213,000. Klingenstein Fields & Co. LLC purchased a new stake in shares of Exelixis in the 4th quarter worth $213,000. Caxton Associates LP purchased a new stake in shares of Exelixis in the 2nd quarter worth $227,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Exelixis in the 3rd quarter worth $236,000. Institutional investors and hedge funds own 80.60% of the company’s stock.

Shares of Exelixis, Inc. (EXEL) opened at $30.22 on Friday. The firm has a market capitalization of $8,940.00, a price-to-earnings ratio of 61.67, a P/E/G ratio of 0.85 and a beta of 1.84. Exelixis, Inc. has a 12 month low of $18.03 and a 12 month high of $32.50.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.18. The firm had revenue of $152.50 million during the quarter, compared to analysts’ expectations of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The firm’s quarterly revenue was up 145.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.04) EPS. analysts forecast that Exelixis, Inc. will post 0.49 EPS for the current year.

In related news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total transaction of $454,500.00. Following the completion of the sale, the director now directly owns 64,829 shares in the company, valued at approximately $1,964,318.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.10% of the company’s stock.

Several brokerages have weighed in on EXEL. BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Oppenheimer restated a “hold” rating on shares of Exelixis in a research note on Thursday, January 4th. Cann restated a “hold” rating on shares of Exelixis in a research note on Thursday, January 4th. Zacks Investment Research upgraded Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price objective for the company in a research note on Tuesday, January 2nd. Finally, Needham & Company LLC upped their price objective on Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, October 17th. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $32.13.

TRADEMARK VIOLATION NOTICE: “Exelixis, Inc. (EXEL) Shares Bought by Chicago Equity Partners LLC” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/exelixis-inc-exel-shares-bought-by-chicago-equity-partners-llc/1841142.html.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.